(Total Views: 777)
Posted On: 05/03/2025 8:35:27 PM
Post# of 154728
Look @ ESMO from KOL perspective.
These are industry titans.
Decades of experience & contacts.
Formatted 36/48 month data that will change oncology & all solid tumors.
Do you think they're willing to wait 6 weeks to stand around for 45 mins, taking random basic to high-end questions in Munich -- when even 1 oncologist could tie you up for 45 mins -- or would they have strongly encouraged Cytodyn to get LL to market asap, like an Advisory Brd post data compiled...
The news says only Dr.'s & RP are presenting.
The real meetings take place off-site.
Hdqtr's, hotels & etc..
The KOL's are why we have FDA peered mTNBC data. They are not going for a purpose to answer 45 mins of poster talk, overseas. Given the value of this data, KOL's would view it as an extremely unorganized waste of time.
KOL's & FDA for right now, are the validating opinions on 36/48 MOA, & to historic deals @ Cytodyn.
Be it -- FDA/EU/WHO/GSK/GF/Canada, etc., etc..
These are industry titans.
Decades of experience & contacts.
Formatted 36/48 month data that will change oncology & all solid tumors.
Do you think they're willing to wait 6 weeks to stand around for 45 mins, taking random basic to high-end questions in Munich -- when even 1 oncologist could tie you up for 45 mins -- or would they have strongly encouraged Cytodyn to get LL to market asap, like an Advisory Brd post data compiled...
The news says only Dr.'s & RP are presenting.
The real meetings take place off-site.
Hdqtr's, hotels & etc..
The KOL's are why we have FDA peered mTNBC data. They are not going for a purpose to answer 45 mins of poster talk, overseas. Given the value of this data, KOL's would view it as an extremely unorganized waste of time.
KOL's & FDA for right now, are the validating opinions on 36/48 MOA, & to historic deals @ Cytodyn.
Be it -- FDA/EU/WHO/GSK/GF/Canada, etc., etc..
(19)
(0)
